• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drug & Device Pipeline News

Drug & Device Pipeline News

March 14, 2022
Company Drug/Device Medical Condition Status
Trials Authorized
Aravax PVX108 Peanut allergy IND approved by the FDA
Inventiva Lanifibranor plus empagliflozin Type 2 diabetes and noncirrhotic nonalcoholic steatohepatitis (NASH) IND approved by the FDA
Insightec Exablate Neuro ultrasound system Nonsmall-cell lung cancer and brain cancer IDE approved by the FDA
Akeso Cadonilimab plus docetaxel Nonsmall-cell lung cancer IND approved by China’s regulatory authority
Antengene ATG-101 Solid tumors and B-cell nonHodgkin’s lymphoma IND approved by China’s regulatory authority
CARsgen Therapeutics CLDN18.2 Gastric and pancreatic cancer Approval for a phase 2 trial granted by China’s regulatory authority
Biomind Labs N, N-dimethyltryptamine (DMT) Treatment-resistant depression Approval for a phase 2 trial granted by Brazil’s regulatory authority
Altamira Therapeutics Bentrio preventive nasal spray COVID-19 Approval for a clinical trial granted by Bulgaria’s regulatory authority
Trials Initiated
Pionyr Immunotherapeutics PY314 Solid tumors Initiation of phase 1b trial
Confo Therapeutics CFTX-1554 Neuropathic pain Initiation of phase 1 trial
Digestome Therapeutics DGX-001 Schizophrenia and Parkinson’s disease Initiation of phase 1 trial
MiNK Therapeutics AgenT-797 Solid tumors Initiation of phase 1 trial
Eucure Biopharma YH002 plus YH001 Solid tumors Initiation of phase 1 trial in Australia and China
Denali Therapeutics DNL593 Frontotemporal dementia-granulin Initiation of phase 1/2 trial
Freeline Therapeutics FLT180a Hemophilia B Initiation of phase 1/2 trial
Palleon Pharmaceuticals E-602 Advanced cancers Initiation of phase 1/2 trial
Aldeyra Therapeutics ADX-2191 Retinitis pigmentosa Initiation of phase 2 trial
Pfizer Paxlovid COVID-19 Initiation of phase 2/3 pediatric trial
Equillium Itolizumab Acute graft-versus-host disease Initiation of phase 3 trial
KalVista Pharmaceuticals KVD900 Hereditary angioedema Initiation of phase 3 trial
Approvals
Bristol Myers Squibb Opdivo (nivolumab) Nonsmall-cell lung cancer in the neoadjuvant setting Approved by the FDA for expanded indication
Antengene Xpovio (selinexor) Relapsed and/or refractory multiple myeloma and triple-class refractory multiple myeloma Approved in Australia

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing